Nasus Pharma (NSRX) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Citizens | Maintained | Market Outperform | $18.00 from $19.00 | Mar 26, 2026 |
| Citizens | Initiated Coverage | Market Outperform | $19.00 | Dec 18, 2025 |
| Laidlaw & Co. | Initiated Coverage | Buy | $22.00 | Sep 29, 2025 |
Frequently asked questions
Is NSRX a buy, sell, or hold?
Analysts covering Nasus Pharma currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on NSRX?
On Mar 26, 2026, Citizens maintained Nasus Pharma at Market Outperform with a price target of $18.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.